Benhexyphenidyl hydrochloride tablets

This product is a central anticholinergic anti-Parkinson's disease drug that selectively blocks the cholinergic nerve pathways in the striatum, but has less effect on the periphery, thus helping to restore the balance of dopamine and acetylcholine in the brain of Parkinson's patients and improve the patients' Parkinson's disease symptoms.

The main ingredient of this product is benzhexol hydrochloride.

This product is white tablets.

It is used for Parkinson's disease and Parkinson's syndrome. It can also be used for extrapyramidal disorders caused by drugs.

Oral. Parkinson's disease and Parkinson's syndrome: start with 1-2 mg per day, then increase by 2 mg every 3-5 days until the best effect is achieved without side effects. Generally, no more than 10 mg per day, divided into 3-4 doses, must be taken for a long time. The maximum daily dose is 20 mg. Drug-induced extrapyramidal disorders: 2-4 mg on the first day, divided into 2-3 doses, then gradually increase to 5-10 mg according to needs and tolerance. Elderly patients should reduce the dose as appropriate.

Common symptoms include dry mouth, blurred vision, etc., and occasionally tachycardia, nausea, vomiting, urinary retention, constipation, etc. Long-term use may cause drowsiness, depression, memory loss, hallucinations, and clouded consciousness.

Patients with glaucoma, urinary retention, and prostatic hypertrophy.

Precautions for children: Use with caution. Precautions for pregnancy and lactation: Use with caution. Precautions for the elderly: Long-term use in the elderly is likely to induce glaucoma. People with arteriosclerosis are prone to mental confusion, disorientation, anxiety, hallucinations and psychotic symptoms when taking the commonly used doses of anti-Parkinson's drugs. Use with caution.

1. When this product is used together with ethanol and central nervous system depressants, it can enhance the sedative effect. 2. When this product is used together with amantadine, anticholinergic drugs or other drugs with anticholinergic effects, monoamine oxidase inhibitors including furazolidone, pargyline and procarbazine, it can enhance the anticholinergic effect of anti-parkinsonian drugs and may cause paralytic ileus. 3. When this product is used together with antacids or adsorbent antidiarrheal agents, it can weaken the efficacy of anti-parkinsonian drugs. When it is necessary to use them, there should be at least 12 hours between the two. 4. When this product is used together with levodopa or its compound preparations, it can enhance the efficacy of levodopa. It should not be used together in patients with a history of mental illness. 5. When this product is used together with chlorpromazine, the latter's metabolism is accelerated, but due to the slowing of gastrointestinal motility, its blood drug concentration can be reduced. 6. When this product is used together with cardiac glycosides, the latter can prolong its residence time in the gastrointestinal tract, increase absorption, and be prone to poisoning.

Keep sealed.

2 mg

36 months

Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd.

• Founded in:

  1994-03-14

• Address:

  No. 9 Jiuzhou Road, Boshan District, Zibo City, Shandong Province

• Tax NO.:

  913703041641044634

• Registered Funds:

  416.6098 million yuan

• Email:

  Log in to view